Found: 3
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2020
Musaelyan A.A., Nazarov V.D., Lapin S.V., Chistyakov I.V., Komarov I.V., Tkachenko O.U., Sogoyan M.V., Berdnik E.W., Mazing A.V., Emanuel W.L., Akopov A.L., Orlov S.V., Bagnenko S.F.
Background. Lung cancer is the most frequent cause of cancer mortality. The prevailing type is non-small cell lung cancer (NSCLC), in the treatment of which EGFR tyrosine kinase inhibitors are actively used, as well as a combination of BRAF and MEK inhibitors.…
ОРИГИНАЛЬНОЕ ИССЛЕДОВАНИЕ2015
Kit O.I., Gevorkyan Yu.A., Soldatkina N.V., Vodolazhsky D.I.
Introduction. KRAS mutations play a critical role in human tumorigenesis and are the most prevalent in colorectal cancer. Because KRAS is the most frequently mutated factor downstream of the EGFR signaling pathway, it was considered to be a candidate molecular…
Research article2013
Mazurenko N.N., Tsyganova I.V., Gagarin I.M., Chuev I.V., Mochalnikova V.V., Kolomeytseva A.A., Gorbunova V.A.
Last successful results in target therapy of cancer were achieved with different tyrosine kinases inhibitors (TKI). Target therapy of non-small cell lung cancer (NSCLC) with EGFR inhibitors gefitinib and erlotinib is effective only in patients with somatic mut…